Brain fog is a recognised cluster of cognitive symptoms — including mental fatigue, difficulty concentrating, word-finding problems, and impaired short-term memory — that can significantly affect daily functioning, and hyperbaric oxygen therapy (HBOT) has demonstrated meaningful clinical potential in addressing several of its underlying physiological causes. While HBOT is not a cure for neurodegenerative disease or a guaranteed resolution for every patient, physician-supervised hyperbaric oxygen therapy has shown promising results in improving cognitive scores, reducing neuroinflammation, and supporting the brain’s own repair mechanisms in carefully selected patients.
For many of our international patients arriving at Holina Clinic, brain fog is not a minor inconvenience — it is a career-limiting, relationship-affecting, quality-of-life issue that conventional medicine has often struggled to address with precision. The frustration is understandable: you may have had blood tests return within normal ranges, been told you simply need better sleep or less stress, and yet you continue to experience that persistent mental heaviness, the word that sits just out of reach, the meeting you left having retained almost nothing. Brain fog is not a formal medical diagnosis, but it is a clinically meaningful symptom cluster, and its causes are frequently rooted in measurable physiological dysfunction.
The most common drivers of cognitive fog include long COVID-related neurological injury, hormonal shifts during perimenopause and menopause, subclinical thyroid dysfunction, chronic sleep deprivation, prolonged psychological stress, and mitochondrial dysfunction — a state in which the brain’s energy-producing cells are simply not generating sufficient ATP to sustain optimal cognitive performance. Each of these pathways, while distinct in origin, shares a common consequence: the brain is not receiving the oxygen, metabolic support, or neurochemical signalling it requires to function at full capacity.
This is precisely where the clinical rationale for HBOT and cognitive decline becomes compelling. Hyperbaric oxygen therapy works by delivering 100% medical-grade oxygen at increased atmospheric pressure, substantially elevating the dissolved oxygen concentration in the blood plasma and cerebrospinal fluid. This hyperoxic state directly increases cerebral oxygenation in under-perfused regions of the brain — areas that imaging studies have shown to be metabolically compromised in patients with long COVID, chronic fatigue, and age-related cognitive decline. Beyond simply flooding the brain with oxygen, HBOT has been shown to reduce neuroinflammation, a key driver of cognitive impairment, by modulating inflammatory cytokine activity and supporting the integrity of the blood-brain barrier.
Critically, HBOT also stimulates neuroplasticity — the brain’s capacity to reorganise, form new neural connections, and repair damaged tissue. This occurs in part through the upregulation of brain-derived neurotrophic factor (BDNF), a protein essential to the growth, maintenance, and survival of neurons. In practical terms, this means that hyperbaric oxygen therapy for brain fog is not simply a symptomatic intervention — it is addressing structural and biochemical conditions that contribute to cognitive underperformance.
The clinical evidence supporting this mechanism is growing. A landmark trial conducted at Shamir Medical Center in Israel examined the effects of HBOT on patients suffering from long COVID cognitive symptoms. The results were significant: participants who underwent a structured course of hyperbaric oxygen sessions demonstrated measurable improvements in cognitive function scores, attention, memory, and executive function compared to a control group — changes that corresponded with improved cerebral blood flow on imaging. This research has substantially strengthened the evidence base for HBOT memory improvement and positioned hyperbaric therapy as a credible, physician-supervised option within an integrated cognitive rehabilitation strategy.
At Holina Clinic, we believe that every patient experiencing cognitive decline deserves a thorough clinical assessment before any treatment is recommended. Brain fog has many causes, and a personalised treatment approach — one that accounts for your medical history, hormonal profile, inflammatory markers, sleep architecture, and lifestyle — is the only responsible foundation for a meaningful outcome. HBOT forms one important part of that clinical picture, and for many of our patients, it has proven to be a genuinely transformative component of their recovery.
What Is Brain Fog and What Is Actually Happening in Your Brain?
Brain fog is not a medical diagnosis in its own right, but rather a recognised cluster of neurological symptoms that signal your brain is not functioning at its optimal capacity. It encompasses cognitive fatigue, difficulty concentrating, problems retrieving words mid-sentence, short-term memory lapses, and a persistent sense of mental sluggishness that interferes with daily life.
Understanding what is occurring at a physiological level is essential before exploring any clinical intervention. When patients describe brain fog, they are frequently describing the downstream consequences of disrupted cerebral oxygenation, neuroinflammation, mitochondrial inefficiency, or hormonal dysregulation — often several of these simultaneously. The brain is extraordinarily energy-demanding, consuming roughly 20% of the body’s total oxygen supply despite representing only 2% of body weight. When oxygen delivery, mitochondrial function, or inflammatory signalling becomes impaired, cognitive performance deteriorates in ways that are measurable, distressing, and — importantly — often addressable through evidence-based clinical care.
The causes of brain fog are numerous and frequently overlapping. Long COVID has brought this symptom cluster to widespread public attention, with a significant proportion of post-COVID patients reporting persistent cognitive difficulties months after the initial infection resolves. Researchers at the Shamir Medical Center conducted a randomised, controlled trial examining the effects of hyperbaric oxygen therapy on long COVID patients experiencing neurological symptoms; participants who received HBOT demonstrated meaningful improvements in cognitive function, attention, and memory scores compared to those in the control group — findings that have contributed to growing clinical interest in oxygen-based interventions for post-viral cognitive impairment.
Beyond long COVID, brain fog is commonly associated with menopause and perimenopause, where fluctuating oestrogen levels directly affect neurotransmitter activity and cerebral blood flow. Thyroid dysfunction — both hypothyroidism and subclinical thyroid dysregulation — is a frequently overlooked contributor, as thyroid hormones regulate neuronal metabolism at a cellular level. Chronic sleep deprivation impairs the brain’s glymphatic clearance system, which is responsible for removing metabolic waste products including amyloid proteins during deep sleep. Prolonged psychological stress elevates cortisol, which in sustained excess is neurotoxic to the hippocampus, the brain region central to memory consolidation. Mitochondrial dysfunction — whether arising from nutrient deficiency, oxidative stress, or metabolic disease — reduces the ATP production that neurons require to fire efficiently.
It is worth being clinically transparent at the outset: brain fog associated with progressive neurodegenerative conditions such as Alzheimer’s disease or Parkinson’s disease represents a fundamentally different pathological process. No intervention — including hyperbaric oxygen therapy — should be presented as a treatment that reverses or halts neurodegeneration. What personalised, physician-supervised assessment can achieve is the identification of modifiable contributors to cognitive decline and the implementation of evidence-based protocols designed to restore neurological function where the underlying cause is addressable.
HBOT Mechanisms: How Hyperbaric Oxygen Therapy Improves Cognitive Function
Understanding the hyperbaric oxygen therapy mechanism is central to appreciating why it represents a clinically credible approach to cognitive function improvement rather than a passive wellness intervention. When a patient breathes 100% medical-grade oxygen inside a pressurised chamber at 1.5 to 2.0 atmospheres absolute, the partial pressure of oxygen in the blood rises dramatically. At this elevated pressure, oxygen dissolves directly into the plasma, cerebrospinal fluid, and interstitial tissues — bypassing the normal haemoglobin-dependent transport system and reaching brain regions where circulation is compromised or inadequate.
This oxygen-rich environment initiates several interconnected biological processes relevant to neurological recovery. First, it directly addresses cerebral hypoxia — the insufficient oxygen supply that underlies much of the metabolic dysfunction observed in chronic brain fog treatment. Second, the hyperoxic state modulates neuroinflammation by downregulating pro-inflammatory cytokines and supporting blood-brain barrier integrity, reducing the inflammatory burden that impairs synaptic transmission and neural efficiency. Third, and perhaps most consequentially for mental clarity restoration, HBOT upregulates the production of brain-derived neurotrophic factor (BDNF) — a protein that promotes neuronal survival, synaptic plasticity, and the formation of new neural connections.
HBOT also stimulates angiogenesis — the formation of new blood vessels — in oxygen-deprived brain tissue, and activates stem cell mobilisation from bone marrow, both of which contribute to longer-term structural neurological repair. Mitochondrial function is also supported: under hyperoxic conditions, the electron transport chain operates more efficiently, restoring ATP production in neurons that have been chronically under-fuelled. Collectively, these oxygen therapy benefits address the physiological architecture of cognitive decline rather than simply managing its surface symptoms, which is why physician-supervised protocols of adequate duration are consistently associated with more meaningful outcomes than isolated or short-course exposures.
Why Are So Many High-Functioning Adults Experiencing Cognitive Decline Before Their Time?
Brain fog is no longer an occasional complaint confined to the elderly or the seriously unwell — it is now one of the most frequently reported symptoms amongst otherwise healthy, high-achieving adults in their thirties, forties and fifties. Understanding why this is happening, and what it means for your long-term neurological health, is essential before exploring whether any intervention is appropriate for you.
The experience tends to follow a recognisable pattern: you find yourself mid-sentence, unable to retrieve a word you have used a thousand times. You read the same paragraph three times without absorbing it. You arrive at a meeting having prepared thoroughly, yet feel as though your thinking is moving through wet concrete. These are not signs of laziness or stress alone — they are neurological signals that something in your brain’s environment has shifted. The clinical term for this symptom cluster encompasses cognitive fatigue, difficulty with sustained concentration, short-term memory lapses and a pervasive sense of mental sluggishness that does not resolve with rest.
Several well-documented physiological processes can drive this presentation. Mitochondrial dysfunction is increasingly recognised as a central mechanism — when the energy-producing organelles within neurons are compromised, cognitive performance deteriorates measurably, even in the absence of structural brain disease. Chronic psychological stress sustains elevated cortisol levels that are directly toxic to the hippocampus, the region most critical to memory consolidation. Thyroid dysfunction, even at subclinical levels, impairs the speed and efficiency of neural transmission. Hormonal shifts during perimenopause and menopause reduce oestrogen — a neuroprotective hormone — leading to deficits in verbal memory, processing speed and executive function that many women report as sudden and alarming.
Long COVID has brought this issue into sharp public focus. A landmark trial conducted at Shamir Medical Center in Israel demonstrated that hyperbaric oxygen therapy produced statistically significant improvements in cognitive scores amongst long COVID patients, including gains in attention, executive function and processing speed. The proposed mechanisms include reduced neuroinflammation, enhanced cerebral oxygenation and stimulation of neuroplasticity — the brain’s capacity to form and reorganise neural connections. HBOT has also been shown to promote production of brain-derived neurotrophic factor (BDNF), a protein that supports the survival and growth of neurons.
It is important to be clinically honest here: HBOT is not a treatment for neurodegenerative conditions such as Alzheimer’s disease or Parkinson’s disease, and it does not reverse established structural brain damage. What the evidence does support is its potential role in addressing the underlying physiological contributors to functional cognitive impairment — inflammation, oxygen insufficiency and impaired neuroplasticity — within a physician-supervised, personalised treatment framework.
Brain Fog vs. Medical Conditions: When to Seek HBOT vs. Other Treatments
Not all cognitive symptoms are created equal, and one of the most important clinical distinctions a physician must make is whether a patient’s brain fog reflects a reversible, modifiable physiological state — or whether it signals an underlying medical condition requiring a fundamentally different treatment pathway. Making this distinction accurately is what separates responsible chronic brain fog treatment from premature or misdirected intervention.
HBOT is most appropriately considered when cognitive symptoms arise from conditions where neuroinflammation, cerebral hypoxia, or mitochondrial dysfunction are central mechanisms. Post-COVID cognitive impairment, chronic fatigue syndrome, and post-anaesthetic cognitive changes represent presentations where HBOT clinical evidence is actively accumulating and physician-supervised protocols have demonstrated measurable benefit. Similarly, patients with elevated inflammatory markers, documented cerebral blood flow abnormalities, or mitochondrial insufficiency may represent strong candidates for an evidence-based HBOT programme within an integrated care plan.
However, several medical conditions can mimic or exacerbate brain fog and require targeted treatment before or alongside any oxygen-based intervention. Hypothyroidism and subclinical thyroid dysfunction demand hormonal management, not oxygen therapy as a primary response. Significant hormonal imbalance — particularly the oestrogen decline of perimenopause — may be most effectively addressed through personalised hormone optimisation, with HBOT playing a complementary rather than primary role. Clinical depression and anxiety disorders can manifest as profound cognitive impairment and require psychiatric evaluation and, where appropriate, pharmacological or psychological intervention.
Critically, progressive cognitive decline that may indicate early-stage Alzheimer’s disease, vascular dementia, or Parkinson’s disease requires specialist neurological assessment as an immediate priority. HBOT is not an appropriate first-line response to suspected neurodegeneration. At Holina Clinic, every patient presenting with cognitive symptoms undergoes a comprehensive physician-led assessment precisely to navigate these distinctions — ensuring that HBOT is recommended only where it is clinically justified, and that any concurrent conditions receive appropriate, coordinated clinical oversight.
HBOT Success Rates for Cognitive Decline: What Research Shows
The HBOT clinical evidence base for cognitive function improvement has strengthened considerably over the past decade, with several well-designed studies providing meaningful data on outcomes across different patient populations. While it is important to interpret this evidence with clinical precision — distinguishing between the conditions studied and the patient groups most likely to benefit — the overall picture supports HBOT as a credible, physician-supervised intervention for specific forms of cognitive decline.
The most robust data currently available concerns post-COVID cognitive impairment. The randomised controlled trial conducted at Shamir Medical Center in Israel, published in a peer-reviewed journal, demonstrated statistically significant improvements across multiple cognitive domains — including attention, executive function, information processing speed, and memory — in long COVID patients following a structured 40-session HBOT protocol. Neuroimaging confirmed corresponding increases in cerebral blood flow in regions associated with cognitive performance. In practical terms, patients experienced measurable mental clarity restoration in areas that had been functionally compromised since their initial COVID infection.
Research examining HBOT for age-related cognitive decline has also produced encouraging findings. A controlled trial investigating healthy older adults found that a course of HBOT sessions produced significant improvements in attention, information processing speed, and executive function compared to controls — with associated increases in cerebral blood flow in the prefrontal cortex. These findings suggest potential oxygen therapy benefits extending beyond post-viral presentations to include the broader spectrum of age-associated cognitive slowing.
It is important to contextualise these results honestly. Study protocols vary in session number, pressure settings, and patient selection criteria, and outcomes reported in controlled trials may not translate uniformly to every individual. Neurological recovery is influenced by the underlying cause, duration, and severity of cognitive symptoms, as well as the quality of the surrounding clinical programme. At Holina Clinic, personalised treatment protocols grounded in current evidence — combined with consistent physician supervision and progress monitoring — provide the most reliable foundation for achieving meaningful, individual cognitive outcomes.
What Can Patients Realistically Expect From HBOT Treatment for Brain Fog?
Most patients undergoing hyperbaric oxygen therapy for brain fog-related cognitive symptoms report a gradual, progressive improvement rather than an immediate or dramatic change. The clinical reality is that HBOT works through cumulative biological mechanisms — including enhanced cerebral oxygenation, reduced neuroinflammation, and the stimulation of neuroplasticity — meaning that meaningful results typically emerge over a structured course of sessions under physician supervision.
At Holina Clinic, each patient begins with a comprehensive assessment to identify the underlying contributors to their cognitive symptoms before any treatment protocol is designed. Brain fog can arise from a wide range of physiological disruptions — including long COVID sequelae, hormonal changes associated with menopause, thyroid dysfunction, chronic stress, sleep deprivation, and mitochondrial compromise — and the treatment approach is personalised accordingly. There is no single protocol appropriate for every patient, which is precisely why clinical oversight at every stage of the process is essential.
In terms of what the sessions themselves involve, patients breathe 100% medical-grade oxygen inside a pressurised hyperbaric chamber, typically at 1.5 to 2.0 atmospheres absolute (ATA), for sessions lasting approximately 60 to 90 minutes. The increased atmospheric pressure allows oxygen to dissolve directly into the plasma, cerebrospinal fluid, and tissues of the brain, reaching areas where circulation may be compromised. This hyperoxygenated environment has been shown to reduce inflammatory markers, support mitochondrial function, and promote the release of brain-derived neurotrophic factor (BDNF) — a protein critical to neuroplasticity and cognitive resilience.
Research published from the Shamir Medical Center in Israel examined HBOT’s effects on long COVID patients experiencing persistent cognitive impairment. The randomised controlled trial demonstrated statistically significant improvements in attention, executive function, and information processing speed following a structured HBOT protocol. These findings provide important clinical evidence supporting the use of HBOT as part of an integrative approach to cognitive recovery, particularly in post-viral presentations where neuroinflammation is believed to play a central role.
Patients should, however, approach treatment with balanced expectations. HBOT is not a cure for neurodegenerative conditions such as Alzheimer’s disease, nor does it reverse structural brain damage. Its benefit lies in optimising the neurological environment — reducing inflammatory burden, improving cellular energy production, and supporting the brain’s own repair mechanisms. Most patients completing a full protocol of 20 to 40 sessions report improvements in mental clarity, word retrieval, sustained concentration, and overall cognitive energy, though individual responses vary depending on the root cause and chronicity of their symptoms.
Throughout the programme, patients at Holina Clinic are monitored by experienced clinical staff, ensuring that the treatment remains appropriately calibrated to their progress and any emerging needs.
Cost and Treatment Duration: What to Budget for HBOT at Holina Clinic
For international patients considering hyperbaric oxygen therapy as part of a cognitive recovery programme, understanding the financial and logistical commitment involved is an essential part of informed decision-making. At Holina Clinic, we believe in transparent clinical guidance that extends to the practical realities of treatment planning — and that begins with an honest account of what a meaningful HBOT course requires in terms of both time and investment.
Evidence-based protocols for cognitive function improvement typically involve between 20 and 40 individual HBOT sessions, with research from the Shamir Medical Center utilising a 40-session protocol to achieve the statistically significant outcomes documented in peer-reviewed literature. This means that minimum recommended stays at Holina Clinic are generally two to three weeks, with longer programmes of four to five weeks allowing for the full session course alongside complementary clinical support such as nutritional optimisation, sleep assessment, and hormonal review where indicated. Single or minimal-session exposures are not consistent with the biological mechanisms through which HBOT achieves neurological recovery, and physician-supervised guidance on programme length is provided individually based on your clinical assessment.
In terms of cost, HBOT programmes at Holina Clinic are priced to reflect the clinical infrastructure, physician supervision, and personalised treatment design involved — not as a commodity wellness service. Indicative pricing for a structured cognitive support programme, inclusive of clinical assessment, HBOT sessions, and ongoing medical oversight, is available directly from the clinic’s patient team and will be discussed transparently during your initial consultation. Patients are encouraged to factor in accommodation, international travel, and any pre-arrival investigations when budgeting for their stay.
Many patients find that the combination of a clinically purposeful programme within a restorative environment represents meaningful value relative to the cumulative cost of fragmented, inconclusive investigations at home. A detailed, personalised cost breakdown is provided as part of your pre-arrival consultation with the Holina clinical team.
How Do Patients From the UK, Australia, and Canada Access HBOT Treatment at Holina Clinic?
Accessing hyperbaric oxygen therapy at Holina Clinic in Koh Phangan, Thailand, is straightforward for international patients from the UK, Australia, and Canada, with the clinic’s team providing structured support from initial enquiry through to departure. Many patients choose to combine their treatment programme with a broader wellness retreat, making the journey both medically purposeful and personally restorative.
The process typically begins with a remote consultation, during which a physician reviews your medical history, current symptoms, and relevant investigations such as thyroid function panels, inflammatory markers, or previous neurological assessments. This pre-arrival clinical review ensures that HBOT is appropriate for your individual presentation and that any contraindications — including certain respiratory conditions or recent ear surgery — are identified before you travel. Patients are encouraged to bring documentation of prior diagnoses, particularly those relating to long COVID, hormonal changes, or sleep disorders, as this contextual information directly shapes the personalised treatment plan developed on arrival.
For patients from the United Kingdom, direct flights to Bangkok from London, Manchester, or Edinburgh typically take between eleven and thirteen hours, with onward connections to Koh Samui airport taking approximately one hour, followed by a short ferry crossing to Koh Phangan. Australian patients travelling from Sydney, Melbourne, or Brisbane benefit from similarly accessible routing via Bangkok, often with competitive fares given Thailand’s popularity as a long-haul destination. Canadian patients, whether from Toronto, Vancouver, or Calgary, generally connect through a Middle Eastern or Asian hub, with total journey times ranging from sixteen to twenty hours depending on routing.
Treatment programmes at Holina Clinic are structured to accommodate international schedules, with minimum recommended stays of two to three weeks to allow for a clinically meaningful course of HBOT sessions under physician supervision. Research context matters here: the Shamir Medical Center trial, which demonstrated measurable improvements in cognitive scores, attention, and executive function among long COVID patients following a supervised HBOT protocol, used a structured multi-session course rather than isolated treatments. This reinforces the clinical rationale for committing to an adequate duration of therapy rather than a single or minimal exposure.
All treatment is conducted under consistent clinical oversight, with progress assessments built into the programme to monitor cognitive function, energy levels, and subjective symptom change. Patients are not simply placed in a chamber and left to manage alone — each session is part of a broader, evidence-based framework that may integrate nutritional support, sleep optimisation, and stress regulation depending on the underlying contributors to your brain fog. The goal is a clinically grounded, measurable improvement in daily cognitive function and quality of life.
Who Is a Good Candidate for HBOT and How Should You Decide?
Deciding whether hyperbaric oxygen therapy is appropriate for your cognitive symptoms requires careful clinical evaluation rather than self-diagnosis or assumption. The strongest candidates are those whose brain fog has a confirmed or strongly suspected physiological driver — such as long COVID, mitochondrial dysfunction, chronic neuroinflammation, or post-viral cognitive impairment — rather than those seeking a general wellness boost without underlying clinical context.
The first and most important step is a thorough medical assessment conducted by a physician experienced in both hyperbaric medicine and the broader landscape of cognitive health. At Holina Clinic, this means reviewing your full medical history, current symptom burden, relevant investigations such as thyroid function, inflammatory markers, sleep studies where appropriate, and any prior diagnoses. Brain fog is a symptom cluster, not a standalone condition, and identifying the root cause or contributing factors is essential before any treatment protocol is recommended. Without this foundation, even the most clinically sound intervention may deliver suboptimal results.
Patients who tend to respond most meaningfully to HBOT are those presenting with documented post-COVID cognitive impairment, where the research base is increasingly compelling. The Shamir Medical Center randomised controlled trial demonstrated statistically significant improvements in cognitive scores, attention, and executive function among long COVID patients following a structured HBOT programme — providing meaningful clinical evidence that cerebral oxygenation and neuroplasticity mechanisms can translate into measurable cognitive benefit. Similarly, individuals with chronic fatigue syndromes, mitochondrial insufficiency, or elevated neuroinflammatory markers may find that HBOT supports the biological environment needed for cognitive recovery.
It is equally important to be clear about where HBOT has recognised limitations. It is not an appropriate primary intervention for established neurodegenerative diseases such as Alzheimer’s or Parkinson’s, and it should never be positioned as a replacement for pharmacological management of thyroid dysfunction, hormonal imbalance, or other systemic conditions contributing to cognitive symptoms. Honest, evidence-based clinical guidance means acknowledging these boundaries and ensuring patients receive integrated care that addresses all relevant factors simultaneously.
Practical considerations for international patients include treatment duration — most evidence-based protocols involve between 20 and 40 sessions — meaning
Ready to Start Your Recovery Journey?
Our clinical team is available to answer your questions and help you find the right programme for your needs.
Speak with Our Team →






